Ohlendorf, F.; Werner, R.A.; Henkenberens, C.; Ross, T.L.; Christiansen, H.; Bengel, F.M.; Derlin, T.
Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics 2021, 11, 504.
https://doi.org/10.3390/diagnostics11030504
AMA Style
Ohlendorf F, Werner RA, Henkenberens C, Ross TL, Christiansen H, Bengel FM, Derlin T.
Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics. 2021; 11(3):504.
https://doi.org/10.3390/diagnostics11030504
Chicago/Turabian Style
Ohlendorf, Fiona, Rudolf A. Werner, Christoph Henkenberens, Tobias L. Ross, Hans Christiansen, Frank M. Bengel, and Thorsten Derlin.
2021. "Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy" Diagnostics 11, no. 3: 504.
https://doi.org/10.3390/diagnostics11030504
APA Style
Ohlendorf, F., Werner, R. A., Henkenberens, C., Ross, T. L., Christiansen, H., Bengel, F. M., & Derlin, T.
(2021). Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics, 11(3), 504.
https://doi.org/10.3390/diagnostics11030504